HPRA Drug Safety Newsletter Edition 75

Download: hpra-drug-safety-newsletter-edition-75.pdf 256 KB

 The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

  • Withdrawal of fusafungine-containing medicinal products
  • Updated advice on the risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors
  • Risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease (COPD)
  • Risk of hepatitis B reactivations with BCR-ABL Tyrosine Kinase Inhibitors (TKIs)
  • Aflibercept (Zaltrap)-Minimising the risk of ONJ
  • Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter


« Back